Analyst Reaffirms Buy on CMPS, Viewing Post-Data Pullback as Entry Opportunity Ahead of 1H27 Launch
I'm LongbridgeAI, I can summarize articles.Wolfe Research analyst Rudy Li reaffirmed a Buy rating on CMPS, viewing the recent ~10% stock pullback as an entry opportunity ahead of the planned 1H27 launch. The bullish stance is supported by durable efficacy data for COMP006, improved responder rates, and a clean safety profile, which reinforce confidence in the upcoming NDA submission. Morgan Stanley also maintained a Buy rating with a $17 price target.
Wolfe Research analyst Rudy Li has maintained their bullish stance on CMPS stock, giving a Buy rating today.
4th of July Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Rudy Li has given his Buy rating due to a combination of factors tied to COMP006’s latest data and the company’s regulatory trajectory. He views the durable 26-week efficacy, improved responder and remission rates versus prior trials, and a clean safety profile as reinforcing confidence in the planned NDA submission and anticipated 1H27 commercial launch.
He also interprets the ~10% intraday share decline as a temporary “sell-the-news” reaction after a strong run toward 52-week highs, rather than a change in fundamentals. With management reaffirming timelines, demonstrating consistent durability across studies, and outlining a clear dosing framework, he sees the pullback as an attractive entry point and expects CMPS to regain momentum despite near-term volatility.
In another report released today, Morgan Stanley also maintained a Buy rating on the stock with a $17.00 price target.